AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25904635 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant rs705702-G near RAB5B and SUOX
Number of subjects: 485
Study 25905829 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based, peer-delivered stress management intervention (8-week duration)
Number of subjects: 151
Study 25905829 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 151
Study 25906048 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conserving therapy (BCT) with surgical removal of the tumor (lumpectomy) followed by radiation treatment.
Number of subjects: 0
Study 25906048 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiscale modeling to predict breast contour after BCT.
Number of subjects: 0
Study 25906326 — intervention group
Group type: COMPARATOR
Intervention: Cluster I (18 COPD patients)
Number of subjects: 85
Study 25906326 — intervention group
Group type: COMPARATOR
Intervention: Cluster II (45 COPD patients)
Number of subjects: 85
Study 25906326 — intervention group
Group type: COMPARATOR
Intervention: Cluster III (22 COPD patients)
Number of subjects: 85
Study 25907127 — intervention group
Group type: COMPARATOR
Intervention: White non-Hispanics
Number of subjects: 238
Study 25907127 — intervention group
Group type: EXPERIMENTAL
Intervention: African Americans
Number of subjects: 238
Study 25907127 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese Americans
Number of subjects: 238
Study 25907127 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic Americans
Number of subjects: 238
Study 25907127 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic minority FMs
Number of subjects: 238
Study 25907127 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher FM diabetes involvement
Number of subjects: 238
Study 25907127 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes education, support success, and diabetes support network size
Number of subjects: 238
Study 25907145 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement training rehabilitation program
Number of subjects: 25
Study 25907145 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 asymptomatic volunteers)
Number of subjects: 25
Study 25907171 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 80/4.5 μg one inhalation b.i.d.
Number of subjects: 4581
Study 25907171 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 μg one inhalation b.i.d.
Number of subjects: 4581
Study 25907171 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 2 x 160/4.5 μg b.i.d.
Number of subjects: 4581
Study 25907621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10mg/kg every 3 weeks for up to four doses, with maintenance therapy every 3 months until disease progression, unacceptable toxic effect, or death.
Number of subjects: 799
Study 25907621 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 3 weeks for up to four doses, with maintenance therapy every 3 months until disease progression, unacceptable toxic effect, or death.
Number of subjects: 799
Study 25907621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10mg/kg
Number of subjects: 799
Study 25907621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 799
Study 25907994 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BIS R0)
Number of subjects: 25
Study 25907994 — intervention group
Group type: COMPARATOR
Intervention: Volume measurement
Number of subjects: 25
Study 25907994 — intervention group
Group type: COMPARATOR
Intervention: Circumference measurement
Number of subjects: 25
Study 25908064 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD
Number of subjects: 882
Study 25908158 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous GLP-1 levels during liquid meal tests
Number of subjects: 0
Study 25908235 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 4
Study 25908674 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with prior stroke and heart failure
Number of subjects: 5005
Study 25908674 — intervention group
Group type: COMPARATOR
Intervention: Patients without prior stroke
Number of subjects: 5005
Study 25908679 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication incidents identified among primary care patients
Number of subjects: 500
Study 25908679 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 500
Study 25908766 — intervention group
Group type: EXPERIMENTAL
Intervention: GlycA
Number of subjects: 26508
Study 25908766 — intervention group
Group type: EXPERIMENTAL
Intervention: high-sensitivity C-reactive protein
Number of subjects: 26508
Study 25908927 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic glucocorticoids not used
Number of subjects: 386
Study 25908927 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic glucocorticoids used
Number of subjects: 386
Study 25908927 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with systemic glucocorticoids)
Number of subjects: 386
Study 25909192 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg of oral zinc
Number of subjects: 700
Study 25909513 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 63
Study 25909513 — intervention group
Group type: COMPARATOR
Intervention: Other atypical antipsychotics
Number of subjects: 63
Study 25910501 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal bleeding (GIB) after PCI
Number of subjects: 6212
Study 25910501 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy
Number of subjects: 6212
Study 25910501 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal bleeding
Number of subjects: 6212
Study 25910501 — intervention group
Group type: EXPERIMENTAL
Intervention: BARC GIB events
Number of subjects: 6212
Study 25910525 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital Atherectomy System (OAS)
Number of subjects: 443
Study 25910663 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to pay out-of-pocket for histopathologic polyp analysis
Number of subjects: 500
Study 25910663 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing willingness to pay
Number of subjects: 500
Study 25910663 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns of patients unwilling to pay
Number of subjects: 500
Study 25911223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics for pulmonary exacerbation (PEx) treatment
Number of subjects: 123
Study 25911554 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine plus bortezomib and prednisone (1.3 mg/m(2) bortezomib twice weekly for 6 weeks, 90 mg/m(2) bendamustine on days 1 and 4)
Number of subjects: 60
Study 25911554 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine plus bortezomib and prednisone (for patients not candidates for transplantation)
Number of subjects: 60
Study 25911999 — intervention group
Group type: EXPERIMENTAL
Intervention: 118G allele carriers
Number of subjects: 86
Study 25911999 — intervention group
Group type: COMPARATOR
Intervention: 118AA homozygotes
Number of subjects: 86
Study 25912075 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIII Fc fusion protein (rFVIIIFc), starting regimen: twice-weekly prophylaxis (Day 1: 25 IU kg(-1); Day 4: 50 IU kg(-1)); adjusted dose (≤ 80 IU kg(-1)) and dosing interval (≥ 2 days) as needed.
Number of subjects: 71
Study 25912185 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate Healthy Eating Index-2010 (AHEI-2010)
Number of subjects: 196
Study 25912185 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension (DASH)
Number of subjects: 196
Study 25912185 — intervention group
Group type: EXPERIMENTAL
Intervention: Prudent diet pattern
Number of subjects: 196
Study 25912185 — intervention group
Group type: EXPERIMENTAL
Intervention: Western diet pattern
Number of subjects: 196
Study 25912185 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 196
Study 25912185 — intervention group
Group type: EXPERIMENTAL
Intervention: Prudent diet
Number of subjects: 196
Study 25912185 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit consumption
Number of subjects: 196
Study 25912185 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat consumption
Number of subjects: 196
Study 25912208 — intervention group
Group type: COMPARATOR
Intervention: 8-valent HPV6/11/16/18/31/45/52/58 vaccine (Study 1)
Number of subjects: 0
Study 25912208 — intervention group
Group type: COMPARATOR
Intervention: 9-valent HPV6/11/16/18/31/33/45/52/58 vaccine (Study 2)
Number of subjects: 0
Study 25912208 — intervention group
Group type: COMPARATOR
Intervention: qHPV vaccine plus 5-valent HPV31/33/45/52/58 (Study 3)
Number of subjects: 0
Study 25912208 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccine candidates (Studies 1, 2, and 3)
Number of subjects: 0
Study 25912400 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 250
Study 25913550 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept, dosage and duration not available
Number of subjects: 0
Study 25914327 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D QCA
Number of subjects: 114
Study 25914327 — intervention group
Group type: COMPARATOR
Intervention: 2D QCA
Number of subjects: 114
Study 25914872 — intervention group
Group type: EXPERIMENTAL
Intervention: Web Only
Number of subjects: 1683
Study 25914872 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitline Only
Number of subjects: 1683
Study 25914872 — intervention group
Group type: EXPERIMENTAL
Intervention: Web + Quitline
Number of subjects: 1683
Study 25914872 — intervention group
Group type: COMPARATOR
Intervention: Control (printed self-help guide)
Number of subjects: 1683
Study 25915455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BIS)
Number of subjects: 58
Study 25915510 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation into RCA
Number of subjects: 14
Study 25915510 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation into SVG-RCA
Number of subjects: 14
Study 25915616 — intervention group
Group type: COMPARATOR
Intervention: IPTp-MQ (2 doses)
Number of subjects: 0
Study 25915616 — intervention group
Group type: COMPARATOR
Intervention: IPTp-MQ (3 doses) added to CTXp
Number of subjects: 0
Study 25915616 — intervention group
Group type: COMPARATOR
Intervention: CTXp alone
Number of subjects: 0
Study 25915689 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping-motivated marijuana use
Number of subjects: 288
Study 25915689 — intervention group
Group type: COMPARATOR
Intervention: Enhancement or social reasons for marijuana use
Number of subjects: 288
Study 25915780 — intervention group
Group type: EXPERIMENTAL
Intervention: IMMU-132 (17.5 mg/kg; twice weekly × 4 weeks)
Number of subjects: 0
Study 25915780 — intervention group
Group type: EXPERIMENTAL
Intervention: IMMU-132 (dosing schemes: every other week, weekly, or twice weekly)
Number of subjects: 0
Study 25915780 — intervention group
Group type: COMPARATOR
Intervention: Control (nonspecific control)
Number of subjects: 0
Study 25916280 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-weeks ECG Holter monitoring
Number of subjects: 105
Study 25916280 — intervention group
Group type: COMPARATOR
Intervention: 24-hour ECG Holter monitoring
Number of subjects: 105
Study 25916814 — intervention group
Group type: COMPARATOR
Intervention: Single ATP burst (Group 1)
Number of subjects: 154
Study 25916814 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple ATP bursts (Group 2)
Number of subjects: 154
Study 25916910 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary composition in normal-weight subjects
Number of subjects: 18
Study 25916910 — intervention group
Group type: COMPARATOR
Intervention: Salivary composition in obese subjects
Number of subjects: 18
Study 25916910 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial lipid metabolism
Number of subjects: 18
Study 25917561 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg)
Number of subjects: 589
Study 25917561 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg)
Number of subjects: 589
Study 25917561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg)
Number of subjects: 589
Study 25917561 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation P2Y₁₂ receptor antagonists
Number of subjects: 589
Study 25917683 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 8 weeks
Number of subjects: 98
Study 25917683 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater DLPFC activity during CPT
Number of subjects: 98
Study 25917683 — intervention group
Group type: EXPERIMENTAL
Intervention: DLPFC activity
Number of subjects: 98
Study 25918250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (400mg/m², then 250mg/m²) and trastuzumab (3.0 or 4.0mg/kg, then 1.5 or 2.0mg/kg weekly)
Number of subjects: 49
Study 25918250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab and trastuzumab
Number of subjects: 49
Study 25918553 — intervention group
Group type: EXPERIMENTAL
Intervention: Metatranscriptome analysis of subgingival biofilms from progressing sites
Number of subjects: 743000000
Study 25918553 — intervention group
Group type: COMPARATOR
Intervention: Metatranscriptome analysis of subgingival biofilms from stable sites
Number of subjects: 743000000
Study 25918553 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall microbial community analysis
Number of subjects: 743000000
Study 25918556 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD106 (150μg, subcutaneous/intramuscular injections)
Number of subjects: 58
Study 25918556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 25918559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of sirolimus
Number of subjects: 30
Study 25918559 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of sirolimus
Number of subjects: 30
Study 25919461 — intervention group
Group type: EXPERIMENTAL
Intervention: KRN23 (anti-FGF23 antibody) injected subcutaneously every 28 days, dosage 0.05-0.6 mg/kg during dose-escalation and 0.1-1 mg/kg during extension
Number of subjects: 28
Study 25919461 — intervention group
Group type: EXPERIMENTAL
Intervention: KRN23 (anti-FGF23 antibody)
Number of subjects: 28
Study 25921059 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg by mouth daily
Number of subjects: 16
Study 25921689 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF 150 mg once daily
Number of subjects: 40
Study 25921689 — intervention group
Group type: COMPARATOR
Intervention: TDF 300 mg every 48 hours
Number of subjects: 40
Study 25921689 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF 150 mg once daily and TDF 300 mg every 48 hours
Number of subjects: 40
Study 25922544 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous Breathing Trial (SBT)
Number of subjects: 250
Study 25922544 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid balance in the 48 h before SBT
Number of subjects: 250
Study 25922544 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive fluid balance in COPD subgroup
Number of subjects: 250
Study 25923040 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative copeptin levels measured daily until discharge
Number of subjects: 205
Study 25923040 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin <2.5 pmol/L on postoperative day 1
Number of subjects: 205
Study 25923040 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin >30 pmol/L on postoperative day 1
Number of subjects: 205
Study 25923040 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of postoperative copeptin concentrations
Number of subjects: 205
Study 25923090 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TPO positive group (32 patients, 43.2%)
Number of subjects: 74
Study 25923090 — intervention group
Group type: COMPARATOR
Intervention: Anti-TPO negative group (42 patients, 56.8%)
Number of subjects: 74
Study 25923426 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial culture and analysis
Number of subjects: 260
Study 25923426 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of respiratory viruses
Number of subjects: 260
Study 25923426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsusceptibility testing for Streptococcus pneumoniae
Number of subjects: 260
Study 25923426 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent detection of pathogens
Number of subjects: 260
Study 25923549 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9291 (20 to 240 mg once daily)
Number of subjects: 253
Study 25923603 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-protein supplementation
Number of subjects: 0
Study 25923603 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino-acid supplements
Number of subjects: 0
Study 25923603 — intervention group
Group type: EXPERIMENTAL
Intervention: β-hydroxyl β-methylbutyrate (HMB)
Number of subjects: 0
Study 25923731 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 27
Study 25924874 — intervention group
Group type: EXPERIMENTAL
Intervention: PRKACA amplification (triplication)
Number of subjects: 5
Study 25924874 — intervention group
Group type: EXPERIMENTAL
Intervention: PRKACA amplification (duplication)
Number of subjects: 5
Study 25924874 — intervention group
Group type: EXPERIMENTAL
Intervention: Constitutional chromosomal PRKACA gene amplification
Number of subjects: 5
Study 25924934 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP mask at pressures of 5, 10, and 15 cm of H2O
Number of subjects: 10
Study 25924934 — intervention group
Group type: COMPARATOR
Intervention: Oronasal CPAP mask at pressures of 5, 10, and 15 cm of H2O
Number of subjects: 10
Study 25924986 — intervention group
Group type: EXPERIMENTAL
Intervention: Index offspring (adolescent offspring of mothers with type 1 diabetes)
Number of subjects: 581
Study 25924986 — intervention group
Group type: COMPARATOR
Intervention: Control offspring (non-diabetic mothers)
Number of subjects: 581
Study 25924987 — intervention group
Group type: COMPARATOR
Intervention: No weight change
Number of subjects: 3485
Study 25924987 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor weight reduction
Number of subjects: 3485
Study 25924987 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium weight reduction
Number of subjects: 3485
Study 25924987 — intervention group
Group type: EXPERIMENTAL
Intervention: Major weight reduction
Number of subjects: 3485
Study 25924990 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (50 μg) administered after placebo; 4 weeks of treatment with salmeterol 50 μg twice daily.
Number of subjects: 32
Study 25924991 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg in combination with paclitaxel (PTX) and carboplatin (CBDCA)
Number of subjects: 15
Study 25924991 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg in combination with paclitaxel (PTX) and carboplatin (CBDCA)
Number of subjects: 15
Study 25924991 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg and 10 mg/kg in combination with paclitaxel (PTX) and carboplatin (CBDCA)
Number of subjects: 15
Study 25925007 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory, local community approach
Number of subjects: 124
Study 25925007 — intervention group
Group type: EXPERIMENTAL
Intervention: Information communication technology (ICT) approach
Number of subjects: 124
Study 25925351 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS embryos
Number of subjects: 43
Study 25925351 — intervention group
Group type: COMPARATOR
Intervention: Non-PCOS embryos
Number of subjects: 43
Study 25925407 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention package (promotion of antenatal care, adequate nutrition, skilled delivery, healthy newborn care practices)
Number of subjects: 3200
Study 25925407 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention package
Number of subjects: 3200
Study 25925619 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (0.1-2.4 mg/kg every 21 days) as a single agent
Number of subjects: 95
Study 25925619 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin combined with rituximab (375 mg/m2)
Number of subjects: 95
Study 25925619 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (1.0 mg/kg) in CLL
Number of subjects: 95
Study 25925619 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (2.4 mg/kg) in NHL
Number of subjects: 95
Study 25925619 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab combination cohort
Number of subjects: 95
Study 25925619 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 95
Study 25925673 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg/day) for two weeks prior to surgery
Number of subjects: 50
Study 25925749 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus irinotecan (XELIRI) regimen with bevacizumab
Number of subjects: 77
Study 25926311 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive cardiac output monitoring device (NICOM)
Number of subjects: 29
Study 25926352 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative capecitabine (825 mg/m² b.i.d. Monday-Friday), oxaliplatin (50 mg/m² weekly), bevacizumab (5 mg/kg on days 1, 15, and 29), and radiation therapy (50.4 Gy) followed by surgery and postoperative FOLFOX plus bevacizumab (5 mg/kg) every 2 weeks for 12 cycles.
Number of subjects: 53
Study 25926352 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative therapy (capecitabine, oxaliplatin, bevacizumab, and RT) followed by surgery and postoperative FOLFOX plus bevacizumab.
Number of subjects: 53
Study 25926352 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative therapy followed by surgery and postoperative FOLFOX plus bevacizumab.
Number of subjects: 53
Study 25926600 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic doses of danaparoid or fondaparinux for participants with low 4Ts score or intermediate 4Ts score plus negative PF4/H-PaGIA result.
Number of subjects: 526
Study 25926600 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic doses of nonheparin anticoagulants for all others.
Number of subjects: 526
Study 25926600 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative PF4/H-PaGIA result.
Number of subjects: 526